Want to see AU:HCT full AI Analyst Report?
Top Page
Holista Colltech Limited
(Sydney:HCT)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.04
▼(-61.11% Downside)
Action:Downgraded
Date:08/20/26
The score is driven down primarily by weak financial performance (sharp revenue contraction, worsening losses, and sustained negative free cash flow), alongside bearish technicals with the stock trading well below all key moving averages. Valuation is not a clear positive because the negative P/E reflects ongoing losses and no dividend yield support is provided.
Positive Factors
Natural-health product focus
A focused position in collagen, nutraceuticals, and natural-health products gives HCT exposure to wellness applications across both consumer and industrial markets. Its combination of research, formulation, and commercialization can support product development and provide multiple avenues for longer-term revenue generation.
Negative Factors
Severe revenue contraction
The sharp revenue contraction signals substantial weakness in commercial traction and reduces the scale available to absorb fixed operating costs. Continued top-line instability would make it difficult for HCT to leverage its product portfolio, fund development, or establish a reliable path toward sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Natural-health product focus
A focused position in collagen, nutraceuticals, and natural-health products gives HCT exposure to wellness applications across both consumer and industrial markets. Its combination of research, formulation, and commercialization can support product development and provide multiple avenues for longer-term revenue generation.
Read all positive factors
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.61M
Dividend YieldN/A
Average Volume (3M)2.59K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth0.72%
EPS Growth-486.96%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding367,834,350
10 Day Avg. Volume1,557
30 Day Avg. Volume2,586
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)28.04
Price to Sales (P/S)5.45
P/FCF Ratio-20.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Holista Colltech Limited Business Overview & Revenue Model
Company Description
Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food...
How the Company Makes Money
HCT’s core revenue model is centered on monetizing proprietary or in-house developed health and nutraceutical products and ingredients. The company makes money primarily through (1) sales of finished products (e.g., branded or private-label nutrac...
Holista Colltech Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.87M | 5.76M | 5.60M | 5.95M | 8.24M | 8.02M |
| Gross Profit | 1.16M | 770.25K | 87.03K | 370.06K | 4.24M | 1.31M |
| EBITDA | -489.16K | -788.46K | 304.37K | -4.52M | -1.02M | -957.40K |
| Net Income | -3.22M | -948.92K | -84.21K | -4.81M | -1.45M | -1.26M |
Balance Sheet | ||||||
| Total Assets | 3.72M | 5.87M | 3.34M | 3.35M | 5.52M | 6.93M |
| Cash, Cash Equivalents and Short-Term Investments | 564.56K | 2.16M | 21.72K | 59.77K | 117.53K | 1.21M |
| Total Debt | 1.32M | 1.59M | 1.77M | 1.57M | 1.22M | 890.32K |
| Total Liabilities | 6.70M | 6.29M | 6.71M | 6.74M | 3.96M | 3.95M |
| Stockholders Equity | -1.48M | 1.12M | -1.73M | -1.97M | 2.83M | 4.10M |
Cash Flow | ||||||
| Free Cash Flow | -1.45M | -1.52M | -1.02M | -411.67K | -1.19M | -1.72M |
| Operating Cash Flow | -1.28M | -1.35M | -1.01M | -407.12K | -1.11M | -1.68M |
| Investing Cash Flow | -29.88K | -176.36K | 692.12K | -46.70K | -105.69K | 50.35K |
| Financing Cash Flow | 1.86M | 3.65M | 143.75K | 418.42K | 120.85K | 109.49K |
Holista Colltech Limited Technical Analysis
Negative
0.09
Price Trends
0.04
Negative
0.06
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
41.61
Neutral
16.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.61 is Neutral, neither overbought nor oversold. The STOCH value of 16.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HCT.
Holista Colltech Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | AU$236.07M | 23.09 | 56.29% | ― | 160.87% | 188.14% | |
81 Outperform | AU$167.83M | 16.13 | 13.83% | 2.41% | 13.26% | 49.05% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
49 Neutral | AU$33.25M | -0.51 | 13.40% | 1.21% | 8.82% | 55.22% | |
46 Neutral | AU$80.56M | -17.12 | -11.08% | ― | 9.08% | -183.87% | |
39 Underperform | AU$13.61M | -4.25 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$18.32M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:HCT
Holista Colltech Limited
0.04
-0.04
-53.75%
AU:NOU
Noumi Limited
0.12
-0.01
-7.69%
AU:BLS
Bioxyne Limited
1.00
0.59
143.90%
AU:BUB
Bubs Australia Ltd.
0.09
-0.06
-40.00%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-5.00%
AU:CLV
Clover Corporation Limited
1.01
0.39
63.41%
Holista Colltech Limited Corporate Events
Holista Colltech Lifts Margins, Books One-Off Loss as ProImmune Dispute Settled
Aug 31, 2026
Holista Colltech reported a 3.6% rise in group revenue to $2.99 million for the half year to June 2026, with gross margin improving to 44.3% on a better sales mix and cost control. The dietary supplements division drove performance with 12.2% sale...
Holista Colltech absorbs ProImmune settlement as cash management tightens
Jul 29, 2026
Holista Colltech reported quarterly group revenue of about $1.50 million, a slight 0.8% increase, with customer receipts rising 12.9% to approximately $1.48 million on better collections, debt recoveries and new deposits. The company’s opera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.